<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Sobi (SOBI.ST) 宣布，欧洲药品管理局人用药品委员会已采纳积极意见，推荐 Aspaveli 或 pegcetacoplan 的市场授权，用于治疗成人和青少年 C3 肾小管病或原发性免疫复合体增生性肾小管炎患者。CHMP 的推荐基于第三阶段 VALIANT 研究的积极结果。</p>
<p>该公司表示，欧洲委员会的批准决定预计将在 2026 年第一季度作出。Sobi 及其合作伙伴 Apellis Pharmaceuticals, Inc.拥有系统性 pegcetacoplan 的全球共同开发权。</p>
<p>欲获取更多健康新闻，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

APLS

<p>Sobi 宣布，欧洲药品管理局的 CHMP 已对 Aspaveli（pegcetacoplan）用于治疗 C3 肾小管病和原发性免疫复合物膜增生性肾小管炎的市场授权给予了积极意见。该决定基于第三阶段 VALIANT 研究的结果，预计欧洲委员会将在 2026 年第一季度批准。Sobi 和 Apellis Pharmaceuticals 拥有该药物的全球共同开发权</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Sobi (SOBI.ST) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli or pegcetacoplan for the treatment of adult and adolescent patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis. The CHMP recommendation is based on positive results from the Phase 3 VALIANT study.</p>
<div class="lb-trans"><p>Sobi (SOBI.ST) 宣布，欧洲药品管理局人用药品委员会已采纳积极意见，推荐 Aspaveli 或 pegcetacoplan 的市场授权，用于治疗成人和青少年 C3 肾小管病或原发性免疫复合体增生性肾小管炎患者。CHMP 的推荐基于第三阶段 VALIANT 研究的积极结果。</p>
</div><p>The company said the approval decision by European Commission is expected in the first quarter of 2026. Sobi and its partner Apellis Pharmaceuticals, Inc. have global co-development rights for systemic pegcetacoplan.</p>
<div class="lb-trans"><p>该公司表示，欧洲委员会的批准决定预计将在 2026 年第一季度作出。Sobi 及其合作伙伴 Apellis Pharmaceuticals, Inc.拥有系统性 pegcetacoplan 的全球共同开发权。</p>
</div><p>For More Such Health News, visit rttnews.com.</p>
<div class="lb-trans"><p>欲获取更多健康新闻，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Sobi 宣布 CHMP 对 Aspaveli 持积极意见